Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:57 PM
Ignite Modification Date:
2025-12-24 @ 7:57 PM
NCT ID:
NCT07111104
Eligibility Criteria:
Inclusion Criteria:
* Age \>18 years
* Patient with metastatic non-small cell cancer who has received one line of immunotherapy (PEMBROLIZUMAB, ATEZOLIZUMAB and NIVOLUMAB) in stage IV.
* Disease evaluable according to iRECIST v1.1 criteria
* For previously irradiated patients, a non-irradiated lesion evaluable according to iRECIST
* WHO (World Health Organization) score less than or equal to 2.
Exclusion Criteria:
* Composite cancer, small cell lung cancer
* Not metastatic at the time of immunotherapy
* Has already received one line of immunotherapy for non-small cell lung cancer: antibody against Programmed cell Death protein 1 (anti-PD-1), antibody against Programmed Death-Ligand 1 or 2 (anti-PD-L1 and anti-PD-L2), antiboby against Cluster of Differentiation 137 (anti-CD137), antibody against Cytotoxic T-lymphocyte-antigen-4 (anti-CTLA-4)) .
* Second active cancer under treatment
* Immunotherapy for another cancer
* Withdrawal of consent
Non inclusion Criteria:
\- Patients treated with DURVALUMAB, on the basis of its marketing authorisation in non-small cell lung cancer and in the adjuvant treatment of NSCLC treated with concomitant radiochemotherapy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07111104
Study Brief:
Protocol Section:
NCT07111104